TrialCancer science2023

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.

Masakazu Toi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.